In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

MiR-126-3P and MiR-223-3p in Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty, The Prague-18 Genetic Sub-study

Session Cardiac troponins and other biomarkers in acute coronary syndromes

Speaker Zuzana Motovska

Event : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Pharmacotherapy
  • Session type : Rapid Fire Abstracts

Authors : M Hromadka (Plzen,CZ), Z Motovska (Prague,CZ), M Karpisek (Brno,CZ), O Hlinomaz (Brno,CZ), R Miklik (Brno,CZ), F Tousek (Ceske Budejovice,CZ), J Jarkovsky (Brno,CZ), R Rokyta (Plzen,CZ), I Krepelkova (Brno,CZ), J Izakova (Brno,CZ), P Widimsky (Prague,CZ)

Authors:
M Hromadka1 , Z Motovska2 , M Karpisek3 , O Hlinomaz4 , R Miklik5 , F Tousek6 , J Jarkovsky7 , R Rokyta1 , I Krepelkova3 , J Izakova3 , P Widimsky2 , 1Charles University and Univ. Hospital, Department of Cardiology - Plzen - Czechia , 2Charles University Prague, 3rd Faculty of Medicine, Faculty Hospital Kralovske Vinohrady - Prague - Czechia , 3Biovendor, Laboratory Medicine - Brno - Czechia , 4International Clinical Research Center, St. Anne´s University Hospital - Brno - Czechia , 5Masaryk University, University hospital - Brno - Czechia , 6Regional Hospital of Ceske Budejovice - Ceske Budejovice - Czechia , 7Institute of Biostatistics and Analyses of Masaryk University - Brno - Czechia ,

On behalf: the PRAGUE-18 study group

Citation:

Background. Balancing the intensity and duration of antiplatelet therapy according to thrombotic risk is a fundamental need in order to optimize therapy effectiveness and safety. Incorporation of new predictors in thrombotic risk stratification is therefore of a crucial importance for antiplatelet therapy net clinical benefit.

Purpose. The present analysis aimed to evaluate the relation of miR-126-3p and miR-223-3p, new markers of platelet activation,  in order to facilitate prediction of recurrent thrombotic events after acute myocardial infarction (AMI).

Method. The analysis included 598 patients (age median 62 years , men 77.8%) randomized in the Prague-18 study (ticagrelor vs. prasugrel in AIM treated with primary PCI). During the study follow up, 40.6% of patients switched to clopidogrel. Determination of miR was evaluated 24 hours after admission; miR-126-3P and miR-223-3p were normalized by miR-423-3p and miR-150-5p. Quantitative determination of selected miRNAs was performed with a novel microRNA immunoassay method.
Selected miRNAs were compared with key efficacy endpoints (cardiovascular death, nonfatal MI and stroke), stent thrombosis and all hemorrhagic events, and analysed using univariate and multivariate logistic regressions.

Results. Increased values of miR-223-3p were significantly related to the occurrence of combined ischemic endpoint within 30 days [OR (95% CI) 15.739 (2.066; 119.932) p= 0.008] and within one year [3.175 (1.402; 7.186) p= 0.006]. Decreased ratio of miR-126-3P / miR-223-3p was significantly related to the occurrence of combined ischemic endpoint within 30 days [0.137 (0.031; 0.609) p= 0.009] and one year [0.372 (0.169; 0.819) p= 0.014]. MiRNAs were identified as independent predictors even after adjustment for confounding clinical predictors (Study arm, Switch to Clopidogrel, Age, Men, BMI, Smoking, History of Hyperlipidemia, Hypertension, DM, MI, PCI, CABG, Chronic heart failure, Chronic renal failure, Peripheral arterial disease, LBBB, RBBB, TIMI < 3 after PCI, Number of diseased vessels > 1, Stem disease, Suboptimal of failure of PCI, Time to hospital). Adjusted ORs (95% CI) are 11.828 (1.472; 98.011), p=0.022 and 2.394 (1.021; 5.610), p=0.045 for increased value of miR-223-3p and the occurrence of combined ischemic endpoint within 30 days and one year respectively; 0.151 (0.030; 0.757), p=0.022 and 0.407 (0.179; 0.925), p=0.032 for decreased ratio of miR-126-3P / miR-223-3p and the occurrence of combined ischemic endpoint within 30 days and one year respectively. No association between miRNA and bleeding complications was identified.

Conclusion. The miR-223-3p and miR-126-3p to miR-223-3p ratio are strong independent predictors of thrombotic ischemic events and can be used to stratify patients post AMI.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are